University of Pennsylvania

University of Pennsylvania

3451 Walnut Street

Philadelphia, PA 19004

United States

Cooperating Signaling Networks Regulate Cell Survival of Pediatric Ph-like ALL

B cell acute lymphoblastic leukemia (B-ALL) is the most common cancer in children. Despite significant improvements in chemotherapy combinations, approximately 20% of children with high-risk B-ALL will fail their treatments. It is now clear that there are different subtypes of ALL with different genetic mutations. These mutations activate and disrupt pathways within the leukemia cells that allows the cells to grow out of control.

ALK as an Immunotherapeutic Target in Neuroblastoma

Neuroblastoma

Predicting Cytokine Release Syndrome before Chimeric Antigen Receptor Therapy in B Lymphoblastic Leukemia

Leukemia

Background

Anthracycline-Induced Cardiac Toxicity in Pediatric Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML)

Background

Acute myeloid leukemia (AML) is the most life-threatening form of leukemia requiring the most intensive treatment. While advances in its treatment have improved survival, chemotherapy exposure results in significant side effects. One type of drug, anthracyclines, increases the risk for heart complications.

Targeting Metabolism as a Therapeutic Approach for High-Risk MYCN-Driven Neuroblastoma

Neuroblastoma

Background

In 30-percent of neuroblastoma cases aberrant activity of the MYCN-gene is present. Current therapies for high-risk MYCN-driven neuroblastoma are ineffective, and only 40% of children with disease can achieve long-term event-free survival. These realities underscore the urgent need to discover novel therapeutic strategies that are more effective in combating neuroblastoma.

Trib2 in the Pathogenesis of T-ALL

Acute Lymphoblastic Leukemia (ALL)

Organ Motion in Children Requiring Radiotherapy to the Abdomen and Chest

Neuroblastoma

Alex's Lemonade Stand Foundation for Childhood Cancer